Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA. We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.
Tewksbury, US
53 (est)

Key People at Mitralign

Richard J. Omilanowicz

Richard J. Omilanowicz

Adam Groothuis

Adam Groothuis

Vice President
Rick Geoffrion

Rick Geoffrion


Mitralign Locations

Tewksbury, US

Mitralign Metrics

Mitralign Summary

Founding Date


Total Funding

$142 M

Latest funding size

$39.8 M

Time since last funding

5 months


Johnson & Johnson Development Corporation, Medtronic, Giza Venture Capital, Saints Capital, Palisade Capital Management, Forbion Capital Partners, Triathlon Medical Venture Partners, Accelerated Technologies Partners, Oxford Bioscience Partners, Oakwood Medical Investors, AAC Capital Partners, Accelerator Technology Holdings